Recently, Karageorgopoulou et al[27] reported that ERCC1 expression status was significantly prognostic of survival in patients with metastatic or recurrent cervical cancer undergoing cisplatin-based chemotherapy. This evidence concerns the gene ERCC1 and cervical cancer.